Drug General Information
Drug ID	D0SR4G
Former ID	DIB005924
Drug Name	ONT-093
Synonyms	MDR inhibitors, Ontogen; OC-144-093
Drug Type	Small molecular drug
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Discontinued in Phase 1	[546965]
Company	Ontogen Corp
Structure		Download 2D MOL 3D MOL
Formula	C32H38N4O
Canonical SMILES	n1c(c([nH]c1c1ccc(/C=C/COCC)cc1)c1ccc(NC(C)C)cc1)c1ccc(<br />NC(C)C)cc1
CAS Number	CAS 216227-54-2
PubChem Compound ID	6450807
Target and Pathway
Target(s)	Multidrug resistance protein 1	Target Info	Inhibitor	[527635]
KEGG Pathway	ABC transporters
	Bile secretion
	MicroRNAs in cancer
NetPath Pathway	IL2 Signaling Pathway
	TCR Signaling Pathway
Pathway Interaction Database	HIF-1-alpha transcription factor network
Reactome	ABC-family proteins mediated transport
WikiPathways	Nuclear Receptors in Lipid Metabolism and Toxicity
	Abacavir transport and metabolism
	Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation
	Integrated Pancreatic Cancer Pathway
	Allograft Rejection
	Drug Induction of Bile Acid Pathway
	Codeine and Morphine Metabolism
References
Ref 546965	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011621)
Ref 527635	A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.